The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel

Mirte M. Malingré(Meander Medisch Centrum), Jan H.M. Schellens(Utrecht University), Olaf van Tellingen(Dutch Cancer Society), Hilde Rosing(The Netherlands Cancer Institute), Franciska J. Koopman(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Jos H. Beijnen(The Netherlands Cancer Institute), W.W. ten Bokkel Huinink, Ken Duchin(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Martha Swart(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Jan A. Lieverst(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)
Anti-Cancer Drugs
April 1, 2001
10.1097/00001813-200104000-00008
Cited by 32

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884